2000
Group-Specific Antibody Levels Surrounding Invasive Pneumococcal Illness in Children Infected with Human Immunodeficiency Virus
King J, Borkowsky W, Mahidhara N, Madore D, Shapiro E, Rutstein R, Tan T, Farley J, Dankner W, Nachman S, Simoes E, Flynn P, Clemens J, Hamilton R. Group-Specific Antibody Levels Surrounding Invasive Pneumococcal Illness in Children Infected with Human Immunodeficiency Virus. The Journal Of Infectious Diseases 2000, 181: 1817-1821. PMID: 10823792, DOI: 10.1086/315441.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusAntibody levelsSerum samplesPneumococcal illnessImmunodeficiency virusPneumococcal antibody levelsGeometric mean levelsAntibody valuesPneumococcal serotypesIgG antibodiesGroup 4Mean levelsSeroresponsesIllnessChildrenWeeksSerotypesVirusLevelsSerorespondersELISAAntibodies
1999
Pneumococcal vaccines: history, current status, and future directions
Butler J, Shapiro E, Carlone G. Pneumococcal vaccines: history, current status, and future directions. The American Journal Of Medicine 1999, 107: 69-76. PMID: 10451012, DOI: 10.1016/s0002-9343(99)00105-9.Peer-Reviewed Original ResearchConceptsPneumococcal polysaccharide vaccinePolysaccharide vaccinePneumococcal infectionCertain underlying medical conditionsSerious pneumococcal diseaseCommunity-acquired pneumoniaPneumococcal conjugate vaccineUnderlying medical conditionsAnti-pneumococcal antibodiesLarger efficacy trialPrevention of infectionDrug-resistant strainsImmunocompetent childrenPneumococcal diseasePneumococcal vaccineBacterial meningitisConjugate vaccineCase fatalityDNA vaccineInvasive infectionsPneumococcal polysaccharideEfficacy trialsImmune responseMedical conditionsHigh risk
1991
The Protective Efficacy of Polyvalent Pneumococcal Polysaccharide Vaccine
Shapiro E, Berg A, Austrian R, Schroeder D, Parcells V, Margolis A, Adair R, Clemens J. The Protective Efficacy of Polyvalent Pneumococcal Polysaccharide Vaccine. New England Journal Of Medicine 1991, 325: 1453-1460. PMID: 1944423, DOI: 10.1056/nejm199111213252101.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal infectionsPneumococcal polysaccharide vaccinePneumococcal vaccineProtective efficacyPneumococcal infectionCase patientsImmunocompetent patientsPolysaccharide vaccineVaccination historyHospital-based case-control studyPolyvalent pneumococcal polysaccharide vaccineSerious pneumococcal infectionsSite of hospitalizationVaccine protective efficacyPolyvalent pneumococcal vaccineCase-control studyProspective surveillanceRandomized trialsSterile sitesPatientsS. pneumoniaeMedical careStreptococcus pneumoniaeVaccineInfection
1987
Prevention of pneumococcal bacteremia in a child with acquired immunodeficiency syndrome-related complex
WOOD C, MCNAMARA J, SCHWARZ D, MERRILL W, SHAPIRO E. Prevention of pneumococcal bacteremia in a child with acquired immunodeficiency syndrome-related complex. The Pediatric Infectious Disease Journal 1987, 6: 564-566. PMID: 3112723, DOI: 10.1097/00006454-198706000-00015.Peer-Reviewed Original ResearchMeSH KeywordsAIDS-Related ComplexFemaleHumansImmunoglobulin GImmunoglobulins, IntravenousInfantPneumococcal InfectionsSepsis
1986
Risk factors for development of bacterial meningitis among children with occult bacteremia
Shapiro E, Aaron N, Wald E, Chiponis D. Risk factors for development of bacterial meningitis among children with occult bacteremia. The Journal Of Pediatrics 1986, 109: 15-19. PMID: 3088242, DOI: 10.1016/s0022-3476(86)80564-9.Peer-Reviewed Original ResearchConceptsOccult bacteremiaBacterial meningitisInfluenzae type bClinical characteristicsInitial visitLumbar punctureRisk factorsRelative riskHaemophilus influenzae type bYale-New Haven HospitalH. influenzae type bType BChildren's HospitalPossible confounding effectsMeningitisBacteremiaEstimates of riskS. pneumoniaeStreptococcus pneumoniaeLogistic regressionN. meningitidisNeisseria meningitidisHospitalChildrenRisk
1984
Resolving the Pneumococcal Vaccine Controversy: Are There Alternatives to Randomized Clinical Trials?
Clemens J, Shapiro E. Resolving the Pneumococcal Vaccine Controversy: Are There Alternatives to Randomized Clinical Trials? Clinical Infectious Diseases 1984, 6: 589-600. PMID: 6390636, DOI: 10.1093/clinids/6.5.589.Peer-Reviewed Original ResearchA controlled evaluation of the protective efficacy of pneumococcal vaccine for patients at high risk of serious pneumococcal infections.
Shapiro E, Clemens J. A controlled evaluation of the protective efficacy of pneumococcal vaccine for patients at high risk of serious pneumococcal infections. Annals Of Internal Medicine 1984, 101: 325-30. PMID: 6380367, DOI: 10.7326/0003-4819-101-3-325.Peer-Reviewed Original ResearchConceptsIncreased risk of pneumococcal infectionRisk of pneumococcal infectionEfficacy of pneumococcal vaccineSystemic pneumococcal infectionPneumococcal infectionPneumococcal vaccineVaccine protective efficacyIncreased riskProtective efficacyCase-control studyOdds ratioVaccine efficacyHigh riskMatched controlsPatientsInfectionConfounding variablesEfficacyVaccine
1982
Periorbital cellulitis and paranasal sinusitis
SHAPIRO E, WALD E, BROZANSKI B. Periorbital cellulitis and paranasal sinusitis. The Pediatric Infectious Disease Journal 1982, 1: 91-94. PMID: 7177909, DOI: 10.1097/00006454-198203000-00005.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAdolescentBacterial InfectionsCellulitisChildChild, PreschoolDiagnosis, DifferentialHaemophilus InfectionsHumansInfantOrbital DiseasesPneumococcal InfectionsSinusitisConceptsParanasal sinusitisPeriorbital cellulitisHaemophilus influenzae type bInfluenzae type bGroup A StreptococcusPeriorbital swellingVenous obstructionPurulent sinusitisAppropriate therapyClinical presentationOrbital cellulitisInflammatory edemaBacterial etiologyOrbital traumaGroup 2Group 1Group 3Streptococcus pneumoniaeA StreptococcusActual infectionCellulitisSinusitisSkin integrityOrbital contentsType B